Table 1.

A summary of Thimerosal-containing DTaP vaccine administration in comparison to Thimerosal-free DTaP vaccine as a risk factor for ASD adverse event reports in the VAERS

Group examined	Number autism/Autism spectrum disorder events	Net number of doses distributed (1998–2000)	Risk ratio (95% CI)	p-value
Thimerosal-Containing DTaP Vaccine	38	16,335,650
			2.02 (1.15–3.56)	< 0.02
Thimerosal-Free DTaP Vaccine	17	14,794,210